Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- 1 February 2013
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (2), 406-411
- https://doi.org/10.1093/annonc/mds343
Abstract
Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B. A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.] Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar. Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.Funding Information
- Bayer Italy
This publication has 21 references indexed in Scilit:
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh scoreAlimentary Pharmacology & Therapeutics, 2011
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolizationCancer Treatment Reviews, 2011
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver functionCancer Chemotherapy and Pharmacology, 2011
- Advanced hepatocellular carcinoma. Review of targeted molecular drugsAnnals of Hepatology, 2011
- Consensus on the current use of sorafenib for the treatment of hepatocellular carcinomaEuropean Journal of Gastroenterology & Hepatology, 2010
- SorafenibDrugs, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- SorafenibDrugs, 2008
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005